OR WAIT null SECS
Bloomberg Intelligence survey credits increased medication access for potential spike.
According to a report by Bloomberg Intelligence, global obesity medication sales could reach $44 billion by 2030, up from $2.5 billion in 2022. Reportedly, analysts believe this will be the result of increased supply, growing demand, and further product innovation.
The organization also credits Novo Nordisk’s Wegovy and Eli Lilly’s tirzepatide with beginning the trend in an out-of-pocket market.
“Unprecedented demand in obesity coupled with the strong relaunch of Wegovy, which serves as a benchmark for future launches, underpins our upgraded sales view for the market,” says Michael Shah, senior industry analyst, Bloomberg Intelligence. “Our previous scenario, published in February, called for $28 billion in obesity sales in 2030, or $33 billion if we don’t adjust for clinical failure risk.”
Reference: Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence. May 31, 2023/Biopharma Reporter